Preventive effects of CTLA4Ig-overexpressing adipose tissue--derived mesenchymal stromal cells in rheumatoid arthritis

Cytotherapy. 2015 Mar;17(3):271-82. doi: 10.1016/j.jcyt.2014.10.010. Epub 2014 Dec 23.

Abstract

Background aims: Rheumatoid arthritis is a systemic autoimmune disorder. In this study, we first compared the therapeutic effects of syngeneic and xenogeneic adipose tissue-derived stem cells on a collagen-induced arthritis mouse model. Second, we investigated the synergistic preventive effects of CTLA4Ig and adipose tissue-derived mesenchymal stromal cells (ASCs) as a therapeutic substance.

Methods: Arthritis was induced in all groups except for the normal, saline (N) group, using chicken type II collagen (CII). Animals were divided into C (control, saline), H (hASCs), M (mASCs) and N groups (experiment I) and C, H, CT (CTLA4Ig-overexpressing human ASC [CTLA4Ig-hASCs]) and N groups (experiment II), according to transplanted material. Approximately 2 × 10(6) ASCs or 150 μL of saline was intravenously administered on days 24, 27, 30 and 34, and all animals were killed on days 42 to 44 after CII immunization.

Results: Anti-mouse CII autoantibodies were significantly lower in the H, M and CT groups than in the C group. Cartilage damage severity score and C-telopeptide of type II collagen were significantly lower in the CT group than in the C group. The serum levels of IL-6 were significantly lower in the H, M and CT groups than in the C group. The serum levels of keratinocyte chemoattractant were significantly lower in the CT group than the C group.

Conclusions: There were similar effects of ASCs on the decrease of anti-mouse CII autoantibody levels between syngeneic and xenogeneic transplantations, and CTLA4Ig-hASCs showed synergistic preventive effects compared with non-transduced hASCs.

Keywords: CTLA4Ig; adipose tissue–derived mesenchymal stromal cells; autoimmune disease; collagen-induced arthritis; rheumatoid arthritis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abatacept / metabolism
  • Abatacept / therapeutic use*
  • Adipose Tissue / cytology
  • Adipose Tissue / immunology
  • Animals
  • Antibodies / immunology
  • Arthritis, Experimental / chemically induced
  • Arthritis, Experimental / therapy*
  • Arthritis, Rheumatoid / therapy*
  • Autoantibodies
  • Cell- and Tissue-Based Therapy*
  • Collagen Type I
  • Collagen Type II / immunology
  • Disease Models, Animal
  • Humans
  • Interleukin-6 / blood
  • Male
  • Mesenchymal Stem Cell Transplantation*
  • Mesenchymal Stem Cells / cytology
  • Mesenchymal Stem Cells / metabolism
  • Mice
  • Mice, Inbred DBA
  • Peptides
  • Stem Cells
  • Transplantation, Heterologous
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies
  • Autoantibodies
  • Collagen Type I
  • Collagen Type II
  • Interleukin-6
  • Peptides
  • Tumor Necrosis Factor-alpha
  • collagen type I trimeric cross-linked peptide
  • Abatacept